ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
C.E.R.A. Administered Up To Once Every Four Weeks Maintained Stable Hemoglobin Levels In Dialysis Patients With Chronic Kidney Disease
Roche's
investigational treatment C.E.R.A., administered once every two weeks or
once every four weeks, was shown to maintain stable hemoglobin (Hb) levels
in dialysis patients who had been taking short-acting, frequently
administered epoetin, according to new data from two phase III trials
presented today at the 39th Annual Meeting of the American Society of
Nephrology in San Diego, CA.
The C.E.R.A. trials represent a milestone in anemia management, as this
is the first time an anti-anemia therapy has been studied in dosing
intervals of up to once every four weeks for its initial Food and Drug
Administration (FDA) filing.
"Maintaining hemoglobin levels within target range is important for the
physical well being of the patient," said Nathan Levin, M.D., Medical and
Research Director of the Renal Research Institute, New York and one of the
lead investigators. "Furthermore, these new data showing that factors such
as age, gender and diabetic status of the patient do not diminish the
impact of C.E.R.A., are important, but not unexpected information."
About PROTOS and MAXIMA Phase III Maintenance Studies
The primary objective of the multi-center, phase III maintenance
studies, PROTOS (Patients Receiving C.E.R.A. Once a Month for the
MainTenance Of Stable Hemoglobin) and MAXIMA (Maintenance of HAemoglobin
EXcels with IV Administration of C.E.R.A.), was to demonstrate that
subcutaneous (SC) and intravenous (IV) C.E.R.A. can maintain Hb
concentration in dialysis patients previously maintained on epoetin
alfa/beta therapy when converted from more frequent dosing to either once
every two weeks or once every four weeks with C.E.R.A. Maintenance refers
to the ability of C.E.R.A. to keep dialysis patients' Hb levels within
target range over a defined period of time.
In the studies, patients were randomized to continue their current
treatment regimen or convert to C.E.R.A. once every two weeks or once every
four weeks. The primary endpoint was the mean change in Hb between baseline
and the evaluation period. (Evaluation occurred at week 28 or 29 following
initiation of C.E.R.A. depending on the study protocol.)
In addition, subgroup analyses were conducted for the PROTOS and MAXIMA
trials to determine the impact of age, gender and diabetic status on mean
Hb levels during the evaluation period in patients receiving C.E.R.A. once
every four weeks. In these trials, dosage was adjusted to maintain Hb plus
or minus 1.0 g/dL of the baseline level.
Details for the studies are as follows:
-- SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) Once Every 2
Weeks or Once Monthly Maintains Stable Hb Levels after Converting
Directly from SC Epoetin 1-3 Times per Week in Patients with CKD on
Dialysis (PROTOS) [SA-PO207]
The PROTOS study compared the efficacy of SC C.E.R.A. in maintaining
stable Hb levels in dialysis patients converted directly from SC epoetin
alfa or beta administered up to three times weekly to C.E.R.A.
administered once every two weeks or once every four weeks. For
patients receiving C.E.R.A once every two weeks, the mean difference in
Hb from baseline was 0.52 g/dL in the evaluation period (weeks 29-36)
and 0.68 g/dL during the follow-up period (weeks 37-52). For patients
receiving C.E.R.A. once every four weeks the mean difference in Hb
levels were 0.57g/dL for the evaluation period and 0.76 g/dL during
follow-up. Mean difference in Hb from baseline for epoetin treated
patients was 0.57 g/dL for the evaluation period and 0.68 g/dL during
follow-up. These data demonstrate that once every four week dosing of
C.E.R.A. was as effective as frequently dosed (1-3 times per week)
epoetin alfa or beta.
-- SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) Administered
up to Once Monthly in Patients with CKD on Dialysis Maintain Adequate Hb
Levels Regardless of Age, Gender or Diabetic Status (PROTOS) [SA-PO210]
In this subgroup analysis of the PROTOS trial, the mean Hb levels
between patients taking C.E.R.A. once every four weeks and frequently
dosed epoetin were similar regardless of age (patients
CERA administrat de pânã la o datã la patru sãptãmâni menþinut stabil în nivelurile de hemoglobinã de dializã pacienþii cu boalã renalã cronicã - C.E.R.A. Administered Up To Once Every Four Weeks Maintained Stable Hemoglobin Levels In Dialysis Patients With Chronic Kidney Disease - articole medicale engleza - startsanatate